Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway.

Tomoka TakaoHirotaka MasudaTakashi KajitaniFumie MikiKaoru MiyazakiYushi YoshimasaSatomi KatakuraShoko TomisatoSayaka UchidaHiroshi UchidaMamoru TanakaTetsuo Maruyama

Published in: Stem cell research & therapy (2022)

Our results suggest that HHUA is a useful cell line for discovery and identification of endometrial CSC-selective drugs, and that sorafenib may be an effective anti-endometrial cancer drug targeting endometrial CSCs.

Keyphrases

endometrial cancer
stem cells
small molecule
signaling pathway
cell proliferation
cancer therapy
transcription factor
high throughput
drug induced
cell therapy
cancer stem cells
emergency department
bioinformatics analysis
adverse drug
drug delivery
electronic health record